The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

Blood

Volumn 111, Issue 10, 2008, Pages 5093-5100

  Scuto, Anna ^a   Kirschbaum, Mark ^a   Kowolik, Claudia ^a   Kretzner, Leo ^a   Juhasz, Agnes ^a   Atadja, Peter ^b   Pullarkat, Vinod ^a   Bhatia, Ravi ^a   Forman, Stephen ^a   Yen, Yun ^a   Jove, Richard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP G PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; PANOBINOSTAT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR GADD45A; TRANSCRIPTION FACTOR GADD45B; UNCLASSIFIED DRUG; GADD45G PROTEIN, HUMAN; HISTONE; HYDROXAMIC ACID; SIGNAL PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; ACETYLATION; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LYMPHATIC LEUKEMIA; METABOLISM; PATHOLOGY;

ACETYLATION; APOPTOSIS; DNA DAMAGE; GENE EXPRESSION REGULATION; HISTONES; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELLS, CULTURED;

EID: 46749139575     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-117762     Document Type: Article

References (54)

1. Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquiti-nation: role in the control of protein stability. Bioessays. 2005;27:408-415.
2. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem. 2004;93:57-67.
3. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
4. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003;22:6489-6496.
5. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol. 2002;9:322-332.
6. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18.
7. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005;96:293-304.
8. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase in hibitors as anticancer agents: a review. Mol Pharmacol. 2005;68:917-932.
9. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Glinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495-528.
10. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
11. Johansson B, Mertens F, Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. Ann Med. 2004;36:492-503.
12. Randolph TR. Advances in acute lymphoblastic leukemia. Clin Lab Sci. 2004;17:235-245.
13. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217-2224.
14. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM. Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:1897-1903.
15. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216-1230.
16. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001 ;15:163-205.
17. Yavuz S, Paydas S, Disel U, Sahin B. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am JTher. 2006;13:389-393.
18. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944-950.
19. Ying J, Srivastava G, Hsieh WS, et al. The stressresponsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res. 2005;11:6442-6449.
20. Heale BS, Soifer HS, Bowers C, Rossi JJ. siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (http://nar.oxfordjournals.org). 2005;33:e30.
21. Scherer LJ, Yildiz Y, Kim J, Cagnon L, Heale B, Rossi JJ. Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther. 2004;10:597-603.
22. Thiriet C, Hayes JJ. Chromatin in need of a fix:phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell. 2005;18:617-622.
23. Wassmann B. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann [Letter]. Drugs. 2007;67:2656.
24. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Then 2007;29:2289-2308.
25. George P Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005;105:1768-1776.
26. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66:5781-5789.
27. Scuto A, Annavarapu S, Bali P, et al. Synergistic cytotoxic effects of a combination of a novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells [abstract]. Blood (ASH Annual Meeting Abstracts). 2004;104:546a. Abstract no. 1977.
28. Bernhard D, Ausserlechner MJ. Tonko M, et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. Faseb J. 1999;13:1991-2001.
29. Murata M, Towatari M, Kosugi H, et al. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn J Cancer Res. 2000;91:1154-1160.
30. Batova A, Shao LE, Diccianni MB. et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002;100:3319-3324.
31. Romanski A, Bacic B, Bug G, et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica. 2004;89:419-426.
32. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589. a novel cinnamic hydrox-amic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635.
33. Ouwehand K, de Ruijter AJ, van Bree C, Caron HN, van Kuilenburg AB. Histone deacetylase inhibitor BL1521 induces a G1 -phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett. 2005;579:1523-1528.
34. Catley L, Weisberg E, Kiziltepe T, et al. Aggre-some induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441-3449.
35. Chen Z, Clark S, Birkeland M, et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 2002;188:127-140.
36. Hirose T, Sowa Y, Takahashi S, et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by
37. transcription factors Oct-1 and NF-Y. Oncogene. 2003;22:7762-7773.
38. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004:101:540-545.
39. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794-2799.
40. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA. GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol. 2002;192:327-338.
41. Jiang F, Wang Z. Gadd45gamma is androgenresponsive and growth-inhibitory in prostate cancer cells. Mol Cell Endocrinol. 2004;213:121-129.
42. Zerbini LF, Czibere A, Wang Y, et al. A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res. 2006;66:11922-11931.
43. Sun L, Gong R, Wan B, et al. GADD45gamina, down-regulated in 65% hepatocellular carcinoma (HCC) from 23 Chinese patients, inhibits cell growth and induces cell cycle G2/M arrest for hepatoma Hep-G2 cell lines. Mol Biol Rep. 2003;30:249-253.
44. Chung HK, Yi YW, Jung NC, et al. Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. J Clin Endocrinol Metab. 2003;88:3913-3920.
45. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methyl-ation. Oncogene. 2004;23:936-944.
46. Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab. 2002;87:1262-1267.
47. Amundson SA, Zhan Q, Penn LZ, Fornace AJ Jr. Myc suppresses induction of the growth arrest genes gadd34, gadd45; and gaddl 53 by DNA-damaging agents. Oncogene. 1998;17:2149-2154.
48. Marhin WW, Chen S, Facchini LM, Fornace AJ Jr, Penn LZ. Myc represses the growth arrest gene gadd45. Oncogene. 1997:14:2825-2834.
49. Jin S, Zhao H, Fan F, et al. BRCA1 activation of the GADD45 promoter. Oncogene. 2000;19:4050-4057.
50. Fan W, Jin S, Tong T, et al. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem. 2002;277:8061-8067.
51. Fillingham J, Keogh MC, Krogan NJ. GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol. 2006;84:568-577.
52. Vavrova J, Janovska S, Rezacova M, et al. Proteomic analysis of MOLT-4 cells treated by valproic acid. Mol Cell Biochem. 2007;303:53-61.
53. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006;108:1174-1182.
54. Geng L, Cuneo KG, Fu A, Tu T, Atadja PW, Halla-han DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006:66:11298-11304.